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Abstract: The premenstrual syndrome (PMS) comprises various physical and emotional symptoms 
which are associated with the menstrual cycle. The emotional changes might be due to the variation 
in the levels of BDNF especially lower levels of plasma BDNF may be present at the luteal phase of 
menstrual cycle. To date, no data were present to associate the link between BDNF gene 
polymorphism and PMS among young Menarcheal females. So, the goal of this investigation is to 
find out the possible relationship between BDNF gene polymorphism and PMS among young 
Menarcheal females of Pakistan. A total of 92 menarcheal girls with age range of 11-14yrs met the 
inclusion criteria. All participants were screened for the depression and PMS using Zung’s 
depression scale/ Diagnostic and Statistical Manual of Mental Disorders-IV (DSM IV) criteria and 
world health organization (WHO) criteria for PMS respectively. Genomic DNA was extracted from 
oral samples by Salting out method and BDNF genotyping was done using PCR-RFLP analysis. 
Results showed no significant association (χ2=1.685, p-value=0.431) was observed between BDNF 
genotyping and PMS among menarcheal girls. BDNF (rs6265) AA and GA genotypes did not show 
significant association with the risk of PMS. Hence, it was concluded that BDNF gene 
polymorphism may not be associated with the PMS among Pakistani Menarcheal girls.  
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Introduction:  
Premenstrual syndromes (PMS) is typically present in reproductive age women [1] and can be defined as a cluster of 
emotional and physical symptoms occur shortly before each menstrual cycle and resolves at the beginning of menstruation 
[2]. In women, PMS is the main source to cause considerable physical and psychological distress during their 
reproductive years. Although the cause of this distress during menstrual cycle is unclear. The prevalence rate of PMS in 
northern Ethiopia [3], Jordanians [4] Iran and France [5] was 37.0%, 80.2% and 98% and 12% respectively whereas in 
Pakistan 53% of females have PMS permitting to ICD-10 (International Statistical Classification of Diseases and Related 
Health Problems-10) criteria [6]. PMS includes many emotional and behavioral symptoms like nervousness, sadness, 
crying spells, mood swings, irritability, changes in appetite, difficulty in concentration, sleeplessness, mood swings, social 
withdrawal and some physical signs and symptoms like body aches, headache, tiredness, weight gain, abdominal bloating, 
and breast tenderness [7, 8]. To date, more than 150 symptoms of PMS have been identified in which mood swings and 
depressive symptoms are prevalent. The most severe form of PMS is premenstrual dysphoric disorder (PMDD), a 
combination of many psychological and somatic symptoms prompting in the luteal phase resulting in the menstruation 
[9]. 
PMS can be caused by changes in the ovarian steroids and other cyclical hormones which directly intricate in the 
regulation of depressive mood and cognitive functions and can influence the expression of BDNF [10]. In the luteal phase, 
the expression of BDNF was lower may involve in the alteration of hormone response and may develop PMS related 
symptoms [10]. In another study, the increased serum BDNF level was also found in the luteal phase among participants 
with PMDD which may reveal a compensatory mechanism resulting in the consequent improvement of PMDD in the 
follicular phase of menstrual cycle [9].  
The gene for BDNF resided at chromosome no. 11p14.1 belongs to neurotropin family of growth factors and has high 
affinity towards tyrosine kinase B (TrkB) receptors generally present all over the central nervous system [11]. Val66Met 
is the polymorphism in the BDNF gene located at position 196 guanine to adenine (G/A) results in the substituted by of 
Val to Met at codon 66 of Pro-BDNF [12] a highly unstable region which constitutes 110 amino acid [13]. The Met allele 
reduces BDNF activity and leads to depressive life events [14]. The Val to Met substitution affects the activity of brain, 
alter the mood behavior and lead to the development of depression and anxiety [15]. It was found previously that BDNF 
gene polymorphism may be responsible for the development of depression when human BDNF polymorphic gene was 
inserted in female mice anxiety or depressive behaviors increased during the estrous cycle with decline estrogen levels 
[12]. It was also documented that the frequency of G allele (recessive homozygotes) was higher among PMDD in human 
population [16]. However, the association between BDNF gene polymorphism and PMS among menarcheal girls is not 
clear yet. So, the present investigation is the first of its kind to found the potential connection between the BDNF gene 
variant and PMS among menarcheal girls.  
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Materials and Methods  
Study participants   
This study is based on schoole aged girls consisting of 92 participants (40 PMS cases and 52 healthy controls) 
recruited from different schools of Karachi, Pakistan from May-June 2014 with a mean age of 14±1years and had signed 
informed written consent form. Sample size was calculated using online calculator OpenEpi (https: 
//www.openepi.com/SampleSize/SSCC.htm). All participants were screened for the depression using Zung’s depression 
scale [17] and DSMIV (Diagnostic and Statistical Manual of Mental Disorders IV) criteria. PMS was identified according 
to the World Health Organization (WHO) criteria for diagnosing PMS. In this way,  40 PMS and 52 Non PMS subjects 
were recruited. This study was conducted in accordance with the Helsinki declaration and approved by the Board of 
Advance Studies and Research, University of Karachi (01199/2010). All girls who were less than 11yrs and more than 
16yrs, prepubertal and post-menarcheal girls and diseased females are excluded from this study. 
 
Demographics  
Information such as age, socio-economic status, life style, Basal metabolic index (BMI), waist to hip ratio (WHR) 
and dietary profile was obtained using questionnaire. Information regarding menstrual history i.e. menarcheal age, the 
regularity of cycles, length of cycle, and physical manifestations during menstruation was also collected.  
 
DNA isolation  
Saliva samples of all participants were collected into 1.5ml of eppendorf tube and genomic DNA was extracted using 
standard Salting out method.  
 
Genotyping of BDNF (Val66Met, rs6265) polymorphism  
The BDNF gene was amplified by PCR thermal cycler (Veriti, Applied Biosystem, USA) using 4 µl DNA, 10 µl 
master mix (2X) (Fementas, USA), 0.5 µl forward primer (5’-ACTCTGGAGAGCGTGAATGG-3’) and reverse  primers 
(5’-ACTACTGAGCATCACCCTGGA-3’) (Integrated DNA Technologies, Inc. IDT, Coralville, Iowa) each (10 pmole) 
and 5 µl DNA/RNA free water in total 20 µl volume. The temperature profile was 95
 
°C (2 mins), 40 cycles of 95
 
°C (30 
sec), 62 °C (30 sec), 72 °C (30 sec) and final extension 72°C (7 mins). The amplified (171bp) products were then 
electrophoresed (80 volts) in 1.5% agarose gel having 0.45g of agarose in 30ml of 0.5X TBE with 0.5 µg/ml of EtBr 
(ethidium bromide) seen under the electrophoretic amplified products using ChemiDoc-It2 (UVP, UK) Vision works LS 
software (version 7.1). 
RELP was carried out by adding 0.5 µl (5 units) of Eco72I (Fermentas, USA) restriction enzyme, 1ul buffer, 5ul PCR 
products and 3.5ul nuclease free water. The digested fragments of BDNF were electophoretically (80 volts) run on 3% of 
agarose gel and visualized under the same GelDoc with the same condition. The digested fragments were identified using 
50 bp ladder (Thermo scientific, USA). The undigested BDNF products were defined as homozygous dominant having A 
allele (171 bp) in which restriction site was absent whereas two digested products were heterozygous and homozygous 
recessive with 171, 92, 72 bp and 92, 72 bp (G allele) respectively in which restriction sites was present. 
 
Analysis of data  
Any deviation of allele frequencies from predicted was calculated using Hardy-Weinberg equilibrium (HWE). The 
association between BDNF polymorphism and PMS was evaluated using Pearson Chi (χ
2
) square test among menarcheal 
girls. Odds ratios (ORs) along with 95% confidence intervals (CIs) via binary logistic regression analysis were used to 
find out the risk of PMS associated with BDNF genotype. All analyses were executed on SPSS 22 and all values were 
considered significant at p<0.05. 
 
Results 
This study recruited 92 (40 PMS cases and 52 healthy controls)  school going adolescent girls with a mean age of 
14±1years from different schools of Karachi, Pakistan. Of the total samples, 43% were depressed (35% were mild and 8% 
were moderate) while 57% were normal. The overall distribution of samples was described in Table 1. 
 
Table 1: Study participants’ characteristics 
Variables PMS cases Controls 
 
(n) (n) 
BMI     
Normal (18-25)  27 42 
Underweight (< 18) 7 5 
Overweight (25-30) 5 2 
Obesity (> 30) 1 3 
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W/H ratio 
  
Acceptable (<0.85)  34 42 
Unacceptable (>0.85) 6 10 
Menarcheal age 
  
12_14  31 49 
<12 9 3 
Cycle length 
  
Normal (3-7)  2 0 
Short (1-2) 36 47 
Long (> 7) 2 5 
Cycle Regularity      
Yes  30 45 
No  10 7 
Dysmenorrhea  
  
No 16 52 
Yes 24 00 
Depression   
No 26 25 
Mild 4 15 
Moderate 8 9 
Severe 2 3 
    BMI= Basal Metabolic Index, W/H ratio= Waist to Hip ratio 
HWE showed that BDNF genotyping was significantly deviated (χ
2 
= 9.672, P-value = 0.00187) among controls. 
No association (χ
2 
= 1.685, p-value = 0.431) was observed between BDNF genotyping and PMS among menarcheal girls. 
AA (OR = 0.923, 95%CI = 0.052-16.456) and GA (OR = 0.711, 95%CI = 0.043-11.865) genotypes of BDNF were found 
to be protective for PMS (Table 2). 
 
Table 2: Association of BDNF genotyping and PMS among participants  
Genotype PMS cases (n) Controls (n) Pearson χ
2
 P-value Odd ratios (95% CI)* P-value 




GA (Val/Met) 27 38 1.685 0.431 0.711 (0.043-11.865) 0.812 
AA 
(Met/Met) 12 13 
  
0.923 (0.052-16.456) 0.957 
Total 40 52 
    
G-allele 29 40 0.094 0.759 1 
 A-allele 51 64     1.099 (0.601-2.009) 0.759 
Total 80 104     
 
Discussion 
Premenstrual syndrome (PMS) is a multidimensional disorder affects various physiological systems. Several 
biological mechanisms that cause PMS have been proposed. Majority of them emphasize on the gonadal steroids, their 
metabolites and their communications with neurotransmitters and neuro-hormone systems including serotonin, gamma-
Aminobutyric acid (GABA), cholecystokinin (CCK), and the renin-angiotensin-aldosterone system (RAAS). Alterations 
in the responses of these systems to gonadal steroidal fluctuations during the menstrual cycle of women and increased 
sensitivity to variations in steroids may be the cause PMS in susceptible females. Homeostatic disruption and poor 
adaptation may be the basic underlying mechanisms. 
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Our findings suggested that BDNF genotyping deviate significantly in accordance with the Hardy Weinberg principle 
which is in contrary to other findings [18]. No relationship between BDNF genotyping and PMS was found due to the 
small sample size. This pilot study first time report the association between PMS and BDNF genotyping which has not 
been previously testified. However a recent study was done on the plasma variations of BDNF and different phases of 
menstrual cycle among menstruating women with PMS and suggested that BDNF was found to be significantly lower 
during luteal phase of the menstrual cycle [10]. Whereas earlier report has determined the increase incidences of 
depressive episodes and BDNF gene polymorphism [19]. A meta-analysis was conducted on geriatric depression to 
compare the frequency of BDNF polymorphism among cases and psychiatrically healthy controls which suggested that 
individual possess Met allele were at increased risk for geriatric depression than Val/Val homozygotes [20]. However, this 
study is limited to the small sample size. Further research is needed with large sample cohort to confirm the results.   
The study concluded that BDNF genotype may not associated the PMS among Pakistani Menarcheal girls.  
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